MethylGene appoints CMO

Montreal - MethylGene Inc. has appointed Robert E. Martell, M.D., Ph.D., as VP and Chief Medical Officer. Most recently, Dr. Martell was Director of Oncology Global Clinical Research at Bristol-Myers Squibb Company. In this role he worked with moleculartargeted drugs in areas such as multi-target kinase inhibitor, CDK2 inhibitor, and panHER inhibitor programs. He also was significantly involved in the Biologic Licensing Application for Erbitux. Dr. Martell concurrently held an appointment as Assistant Clinical Professor of Oncology at Yale University School of Medicine and Staff Physician at the Veterans Affairs hospital. Previously, Dr. Martell worked at Bayer Pharmaceutical Division; his last position was as Deputy Director Medical Science Unit, where he oversaw the Phase I and Phase II studies for BAY 43-9006 (Sorafenib, a RAF Kinase/VEGF/PDGF inhibitor) and the post-marketing clinical development of Viadur.